Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for International Journal of Endocrinology, enter your email address in the box below.

International Journal of Endocrinology
Volume 2012 (2012), Article ID 167154, 5 pages
http://dx.doi.org/10.1155/2012/167154
Clinical Study

Comparison of ox-LDL Levels in Diabetic Patients with Normo-, Micro-, and Macroalbuminuria with Their First Degree Relatives and the Healthy Control Group

Parisa Behzadi,1 Firouzeh Torabi,1 Massoud Amini,2 and Ashraf Aminorroaya2

1Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2Internal Medicine and Endocrinology, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Sedigheh Tahereh Research Complex, Khorram Street, 8187698191 Isfahan, Iran

Received 13 June 2012; Revised 4 October 2012; Accepted 5 October 2012

Academic Editor: Leon Bach

Copyright © 2012 Parisa Behzadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Yan, J. L. Mehta, W. Zhang, and C. Hu, “LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications,” Cardiovascular Drugs and Therapy, vol. 25, no. 5, pp. 451–459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Gutwein, M. S. Abdel-Bakky, K. Doberstein et al., “CXCL16 and oxLDL are induced in the onset of diabetic nephropathy,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9B, pp. 3809–3825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Turk, M. Šesto, J. Skodlar, G. Ferenčak, N. Turk, and A. Stavljenić-Rukavina, “Soluble LDL-immune complexes in type 2 diabetes and vascular disease,” Hormone and Metabolic Research, vol. 34, no. 4, pp. 196–201, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Tsuzura, Y. Ikeda, T. Suehiro et al., “Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes,” Metabolism, vol. 53, no. 3, pp. 297–302, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Girona, J. M. Manzanares, F. Marimón et al., “Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 5, pp. 380–387, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. S. Mshelia and H. U. Pindiga, “Review article: dyslipidaemia, lipid oxidation, and free radicals in diabetic nephropathy: an overview,” Highland Medical Reaserch Journal, vol. 2, no. 1, 2004. View at Google Scholar
  7. S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, T. Iwasaka, and S. Fukuhara, “Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes,” Clinical and Applied Thrombosis/Hemostasis, vol. 10, no. 3, pp. 205–215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Nosadini and G. Tonolo, “Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 2, pp. 79–85, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Abdelsamie, Y. Li, Y. Huang et al., “Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III,” Clinical Immunology, vol. 139, no. 3, pp. 258–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. J. Quigg, “If oxidized LDL immune complexes are relevant in diabetic atherosclerosis, shouldn't they also be relevant in diabetic nephropathy?” Clinical Immunology, vol. 139, no. 3, pp. 233–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Ujihara, Y. Sakka, M. Takeda et al., “Association between plasma oxidized low-density lipoprotein and diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 58, no. 2, pp. 109–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. American Diabetes Association, “Diabetic nephropathy,” Diabetes Care, vol. 25, supplement 1, p. S86, 2002. View at Google Scholar
  13. O. Vaccaro and G. Riccardi, “Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition,” Diabetes Care, vol. 28, no. 7, pp. 1786–1788, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Sesti, F. Andreozzi, R. C. Bonadonna et al., “Impact of lowering the criterion for impaired fasting glucose on identification of individuals with insulin resistance. The GISIR database,” Diabetes/Metabolism Research and Reviews, vol. 24, no. 2, pp. 130–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Kondo, M. Manabe, K. Saito, M. Maekawa, and T. Kanno, “Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes,” Journal of Atherosclerosis and Thrombosis, vol. 9, no. 6, pp. 280–287, 2002. View at Google Scholar · View at Scopus
  16. P. Holvoet, J. Vanhaecke, S. Janssens, F. Van De Werf, and D. Collen, “Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease,” Circulation, vol. 98, no. 15, pp. 1487–1494, 1998. View at Google Scholar · View at Scopus
  17. M. Nakhjavani, A. Esteghamati, O. Khalilzadeh, F. Asgarani, N. Mansournia, and M. Abbasi, “Association of macroalbuminuria with oxidized LDL and TGF-β in type 2 diabetic patients: a case-control study,” International Urology and Nephrology, vol. 42, no. 2, pp. 487–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Atchley, M. Lopes-Virella, D. Zheng, D. Kenny, and G. Virella, “Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy,” Diabetologia, vol. 45, no. 11, pp. 1562–1571, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Moro, C. Zambon, S. Pianetti, G. Cazzolato, M. Pais, and G. Bittolo Bon, “Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation,” Acta Diabetologica, vol. 35, no. 3, pp. 161–164, 1998. View at Google Scholar · View at Scopus
  20. M. F. Lopes-Virella, R. E. Carter, N. L. Baker, J. Lachin, and G. Virella, “High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes,” Nephrology Dialysis Transplantation, vol. 27, no. 4, pp. 1416–1423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Rashidi, M. Nakhjavani, A. Esteghamati et al., “Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: results in 142 patients,” Journal of Nephrology, vol. 22, no. 6, pp. 733–738, 2009. View at Google Scholar · View at Scopus